The purpose of this review is to familiarize a broad range of medical professionals with a relatively new and growing problem of infections caused by mycobacteria other than M. tuberculosis and M. leprae. There are at least 60 mycobacterial species that have been identified as causative agents of diseases in humans. They are all environmental bacteria, and they are not transmitted from person to person. The usual source of infection is water, soil, and aerosols developed from these sources. The probability of contracting such a disease depends not only on the closeness of interaction with an environment containing an enhanced concentration of bacteria but also and foremost on the sensitivity of an individual to these infections, which may depend on the state of immunity and other so-called predisposing conditions. Therefore, these infections are often referred to as opportunistic, and the group of organisms causing them are usually referred to as nontuberculous mycobacteria (NTM). This review addresses in a condensed form various aspects of these infections, including bacteriology, clinical manifestations, diagnosis, and therapy. The reader will be able to find more details on each of these topics in several reviews and some original papers cited in this article.
KEYWORDS
Mycobacterium
- nontuberculous mycobacteria (NTM) - environmental mycobacteria - infections with opportunistic mycobacteria
REFERENCES
-
1
Amfah G, Bonsu F, Tetteh C et al..
Buruli ulcer in Ghana: results of a national case search.
Emerg Infect Dis.
2002;
8
167-170
-
2
Van der Wert T, Stinear T, Stienstra Y, Van der Graaf W TA, Small P L.
Mycobactones and Mycobacterium ulcerans disease.
Lancet.
2003;
362
1062-1064
-
3
Wolinsky E.
Nontuberculous mycobacteria and associated diseases.
Am Rev Respir Dis.
1979;
119
107-159
-
4
Wayne L G, Sramek H A.
Agents of newly recognized or infrequently encountered mycobacterial diseases.
Clin Microbiol Rev.
1992;
5
1-25
-
5 Goodfellow M, Wayne L G. Taxonomy and nomenclature. In: Ratledge C, Stanford J The Biology of the Mycobacteria, Vol 1. London; Academic 1982: 471-521
-
6
Woods G L, Washington J A.
Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects.
Rev Infect Dis.
1987;
9
275-294
-
7 Goodfellow M, Magee J G. Taxonomy of mycobacteria. In: Gangadharam PRJ, Jenkins PA Mycobacteria, Vol. I: Basic Aspects. New York; Chapman and Hall (International Thomson Publishing) 1998: 1-71
-
8
Tortoli E.
Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of 1990s.
Clin Microbiol Rev.
2003;
16
319-354
-
9 Sneath P HA. International Code of Nomenclature of Bacteria. Washington DC; American Society for Microbiology 1992
-
10
Wallace R J, Glassroth J, Griffith D E, Oliver K N, Cook J L, Gordin F.
Diagnosis and treatment of disease caused by nontuberculous mycobacteria (American Thoracic Society Statement).
Am J Respir Crit Care Med.
1997;
156
1-25
-
11
Good R C, Snider D E.
Isolation of nontuberculous mycobacteria in the United States.
J Infect Dis.
1982;
146
829-833
-
12 Kent P T, Kubica G P. Public Health Mycobacteriology (a guide for the level III laboratory). Atlanta; Centers for Disease Control 1985
-
13 Witebsky F G, Kruczak-Filipov P. Identification of mycobacteria by conventional methods. In: Heifets LB Clinical Mycobacteriology. Philadelphia; WB Saunders 1996: 569-602 Clinics in Laboratory Medicine, Vol 16
-
14 Heifets L B, Jenkins P A. Speciation of mycobacteria in clinical laboratories. In: Gangadharam PRJ, Jenkins PA Mycobacteria, Vol. I: Basic Aspects. New York; Chapman and Hall (International Thompson Publishing) 1998: 308-350
-
15
Rogall T, Flohr T, Böttger E C.
Differentiation of Mycobacterium species by direct sequencing of amplified DNA.
J Gen Microbiol.
1990;
136
1915-1920
-
16
Butler W R, Jost K C, Kilburn J O.
Identification of mycobacteria by high-performance liquid chromatography.
J Clin Microbiol.
1991;
29
2468-2472
-
17
Kirschner P, Springer B, Vogel U.
Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a two year experience in a clinical laboratory.
J Clin Microbiol.
1993;
31
2882-2889
-
18
Thibert L, Lapierre S.
Routine application of high-performance liquid chromatography for identification of mycobacteria.
J Clin Microbiol.
1993;
31
1759-1763
-
19
Glickman S E, Kilburn S O, Butler W R.
Rapid identification of mycolic acid patterns of mycobacteria by high-performance liquid chromatography using pattern recognition software and a Mycobacterium library.
J Clin Microbiol.
1994;
32
740-749
-
20 Roberts G D, Böttger E C, Stockman L. Methods for the rapid identification of mycobacterial species. In: Heifets LB Clinical Mycobacteriology. Philadelphia; WB Saunders 1996: 603-639 Clinics in Laboratory Medicine, Vol 16
-
21
El Amin N M, Hanson H S, Pettersson B, Petrini B, Von Stedink L V.
Identification of nontuberculous mycobacteria: 16S rRNA gene sequense analysis vs. conventional methods.
Scand J Infect Dis.
2000;
32
47-50
-
22
Butler W R, Guthertz L S.
Mycolic acid analysis by high-performance liquid chromatography for identification of Mycobacterium species.
Clin Microbiol Rev.
2001;
14
704-726
-
23
Claud J L, Neal J, Rosenberry R et al..
Identification of Mycobacterium spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries.
J Clin Microbiol.
2002;
40
400-406
-
24
Hall L, Doerr K A, Wohlfiel S L, Roberts G D.
Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribisomal DNA sequencing and its integration into routine clinical mycobacteriology laboratory.
J Clin Microbiol.
2003;
41
1447-1453
-
25
Eisenach K D, Sifford M D, Cave M D, Bates J H, Crawford J T.
Detection of Mycobacterium tuberculosis in sputum samples using polymerase chain reaction.
Am Rev Respir Dis.
1991;
144
1160-1163
-
26
Forbes B A, Hicks K ES.
Direct detection of Mycobacterium tuberculosis in respiratory specimens in a clinical laboratory by polymerase chain reaction.
J Clin Microbiol.
1993;
31
1688-1694
-
27 Shinnick T M, Jonas V. Molecular approach to the diagnosis of tuberculosis. In: Bloom BR Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC; ASM 1994: 517-530
-
28
Pfyffer G E, Kissling P, Wirth R, Weber R.
Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system.
J Clin Microbiol.
1994;
32
918-923
-
29
Desmond E, Loretz K.
Use of the Gen-Probe amplified Mycobacterium Tuberculosis Direct Test for early detection of Mycobacterium tuberculosis in BACTEC 12B medium.
J Clin Microbiol.
2001;
39
1993-1995
-
30
Jost Jr K C, Dunbar D F, Barth S S, Headley V L, Elliot L B.
Identification of Mycobacterium tuberculosis and M. avium complex directly from smear-positive sputum specimens and Bactec 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition models.
J Clin Microbiol.
1995;
33
1270-1277
-
31
Wolinsky E, Rynearson T K.
Mycobacteria in soil and their relation to disease-associated strains.
Am Rev Respir Dis.
1968;
97
1031-1037
-
32
Portaels F.
Epidemiology of mycobacterial diseases.
Clin Dermatol.
1995;
13
297
207-222
-
33
Falkinham J O.
Epidemiology of infection by nontuberculous mycobacteria.
Clin Microbiol Rev.
1996;
9
177-215
-
34 Falkinham J O. Nontuberculous mycobacteria in the environment. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 520-553 Clinics in Chest Medicine, Vol 23
-
35 Marras T K, Daley C L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterisl Infections. Philadelphia; WB Saunders 2003: 553-568 Clinics in Chest Medicine, Vol 23
-
36
Iseman M D, Buschman D L, Ackerson L M.
Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by M. avium complex.
Am Rev Respir Dis.
1991;
144
914-916
-
37
Iseman M D.
Mycobacterium avium complex and the normal host: the other side of the coin.
N Engl J Med.
1989;
321
896-898
-
38
Prince D S, Peterson D D, Steiner R M et al..
Infection with Mycobacterium avium complex in patients without predisposing conditions.
N Engl J Med.
1989;
321
863-868
-
39
Reich J M, Johnson R E.
Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting.
Am Rev Respir Dis.
1991;
143
1381-1385
-
40
Kubo K, Yamazaki Y, Haciya T et al..
Pulmonary M. avium-intracellulare infection in patient without known predisposing lung disease.
Lung.
1998;
176
381-389
-
41
Hawkins C C, Gold W M, Whimbey E et al..
M. avium complex infections in patients with aquired immunodeficiency syndrome.
Ann Intern Med.
1986;
105
184-188
-
42
Nightingale S D, Byrd L T, Southern P M, Jockusch J D, Cal S X, Wynne B A.
Incidence of M. avium-intracellulare complex in human immunodeficiency virus-positive patients.
J Infect Dis.
1992;
165
1082-1085
-
43
Horsburgh C R.
M. avium complex infection in the aquired immunodeficiency syndrome.
N Engl J Med.
1991;
324
1332-1338
-
44
Sanchez T, Vanderkolk J, Seay S, Heifets L.
Quantitation of mycobacteria in blood specimens from patients with AIDS.
Tubercle and Lung Disease.
1994;
75
386-390
-
45
Heifets L B.
Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy (review).
Res Microbiol.
1994;
145
188-196
-
46 Jones D, Havlir D V. Nontuberculouse mycobacteria in HIV infected patient. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 665-674 Clinics in Chest Medicine, Vol 23
-
47
Yates M D, Grange J M, Collins C H.
The nature of mycobacterial disease in south-east England.
J Epidemiol.
1986;
40
295-300
-
48
Bittner M J, Horowitz E A, Safranek T J, Preheim L C.
Emergence of M. kansasii as a leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital.
Clin Infect Dis.
1996;
22
1109-1110
-
49 Griffith D E. Management of disease due to M. kansasii
. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 613-625 Clinics in Chest Medicine, Vol 23
-
50
Byrd R P, Mirza S, Roy T M.
Lady Windermere's syndrome: an atypical presentation of an atypical mycobacterium.
J Tenn Med Assoc.
1995;
88
303-305
-
51
Dhillon S S, Watanakunakorn C.
Lady Windermere Syndrome: middle lobe bronchiectasis and M.avium complex infection due to voluntary cough suppression.
Clin Infect Dis.
2000;
30
572-575
-
52 Levin D L. Radiology of pulmonary M. avium-intracellulare complex. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 603-612 Clinics in Chest Medicine, Vol 23
-
53
Griffith D E, Girard W M, Wallace R J.
Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an anlysis of 154 patiemts.
Am Rev Respir Dis.
1993;
147
1271-1278
-
54 Daley C L, Griffith D E. Pulmonary disease caused by rapidly growing mycobacteria. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 623-632 Clinics in Chest Medicine, Vol 23
-
55
Johnston J M.
Izumi AK Cutaneous M. marinum infection (“swimming pool granuloma”).
Clin Dermatol.
1988;
5
68-75
-
56
Males B M, West T E, Bartolomew W R.
M. haemophilum infection in a patient with aquired immunodeficiency syndrome.
J Clin Microbiol.
1987;
25
186-190
-
57
Rogers P L, Walker R E, Lane H C et al..
Disseminated M. haemophilum infection in two patients with the aquired immunodeficiency syndrome.
Am J Med.
1988;
84
640-642
-
58
Wallace R J.
The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria M. fortuitum and M. chelonae
.
Clin Chest Med.
1989;
10
419-429
-
59
Dautzenberg B, Truffot C, Legris S et al..
Activity of clarithromycin against M. avium infection in patients with aquired immunodeficiency syndrome.
Am Rev Respir Dis.
1991;
144
564-569
-
60
Dautzenberg B, Saint Mark T, Meyohas M C et al..
Clarithromycin and other antimicrobial agents in the treatment of disseminated M. avium infections in patients with aquired immunodeficiency syndrome.
Arch Intern Med.
1993;
153
368-372
-
61
Chaisson R E, Benson C A, Dube M P et al..
Clarithromycin therapy for bacteremic M. avium complex disease: a randomized double-blind, dose-ranging study in patients with AIDS.
Ann Intern Med.
1994;
121
905-911
-
62
Wallace R J, Brown B A, Griffith D E et al..
Initial clarithromycin monotherapy for M. avium-intracellulare complex lung disease.
Am J Respir Crit Care Med.
1994;
149
1335-1341
-
63
Dautzenberg B, Piperno D, Diot P et al..
Clarithromycin in the treatment of M. avium lung infections in patients without AIDS.
Chest.
1995;
107
1035-1040
-
64
Pierce M, Crampton S, Henry D et al..
A randomized trial of clarithromycin as profilaxis against disseminated M. avium complex infection in patients with advanced aquired immunodeficiency syndrome.
N Engl J Med.
1996;
355
384-391
-
65
Oldfield E C, Fessel W J, Dunne M W et al..
Once weekly azithromycin therapy for prevention of M. avium infection in patients with AIDS: a randomized, double-blind, placebo-controlled multi-center trial.
Clin Infect Dis.
1998;
26
611-619
-
66
Cohn D L, Fisher E J, Peng G T et al..
A prospective randomized trial of four three-drug regimens in the treatment of disseminated M. avium complex disease in AIDS patients: excess mortality associated with high dose clarithromycin. Terry Beirn Community Programs for clinical research on AIDS.
Clin Infect Dis.
1999;
29
125-133
-
67
Gordin F M, Sullam P M, Shafran S D et al..
A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with M. avium complex.
Clin Infect Dis.
1999;
28
1080-1085
-
68
Benson C A, Williams P L, Currier J C et al..
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for treatment of disseminated M. avium complex disease in persons with aquired immunodeficiency syndrome.
Clin Infect Dis.
2003;
37
1234-1243
-
69
Chaison R E, Keiser P, Pierce M et al..
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic M. avium complex disease in patients with HIV infection.
AIDS.
1997;
11
311-317
-
70
Ward T T, Rimland D, Kauffman C, Huycke M, Evans T G, Heifets L.
Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for M. avium complex bacteremia in patients with human immunodeficiency virus infection.
Clin Infect Dis.
1998;
27
1278-1285
-
71
Wallace R J, Brown B A, Griffith D E et al..
Clarithromycin regimens for pulmonary M. avium complex.
Am J Respir Crit Care Med.
1996;
153
1766-1772
-
72
Griffith D E, Brown B A, Girard W M et al..
Azithromycin activity against M. avium complex lung disease in patients who were not infected with human immunodeficiency virus.
Clin Infect Dis.
1996;
23
983-989
-
73
Dunne M, Fessel J, Kumar P et al..
A randomized, double-blind trial comparing azithromycyn and clarithromycin in the treatment of disseminated M. avium infection in patients with human immunodeficiency virus.
Clin Infect Dis.
2000;
31
1245-1252
-
74 Iseman M D. Medical management of pulmonary disease caused by M, avium complex. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 633-641 Clinics in Chest Medicine, Vol 23
-
75
Heifets L B, Iseman M D.
Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility.
N Engl J Med.
1990;
323
419
-
76
Heifets L B, Iseman M D.
Individualized therapy vs standard regimens in the therapy of M. avium infections [editorial].
Am Rev Respir Dis.
1991;
144
1-2
-
77 Heifets L B. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton; CRC 1991
-
78
Heifets L.
Susceptibility testing of M. avium complex isolates (review).
Antimicrob Agents Chemother.
1996;
40
1759-1767
-
79
Heifets L B.
Clarithromycin against M. avium complex infections (review).
Tubercle and Lung Disease.
1996;
77
19-26
-
80
Siddiqi S H, Heifets L B, Cynamon M H et al..
Rapid broth macridilution method for determination of MICs for M. avium isolates.
J Clin Microbiol.
1993;
31
2332-2338
-
81
Heifets L, Mor N, Vandercolk J.
M. avium strains resistant to clarithromycin and azithromycin.
Antimicrob Agents Chemother.
1993;
37
2364-2370
-
82
Craft J C, Notario G F, Grosset J H, Heifets L B.
Clarithromycin resistance and susceptibility pattern in M. avium strains isolated during prophylaxis of disseminated infection in patients with AIDS.
Clin Infect Dis.
1998;
2
430-434
-
83
Davidson P, Khanijo V, Goble M et al..
Treatment of disease due to M. intraacellulare
.
Rev Infect Dis.
1981;
3
1052-1059
-
84
Horsburgh C R, Mason U G, Heifets L B et al..
Response to therapy of pulmonary M. avium-intracellulare infection correlates with results of in vitro susceptibility testing.
Am Rev Respir Dis.
1987;
135
418-421
-
85
Tsukamura M.
Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by M. avium complex.
Am Rev Respir Dis.
1988;
137
144-148
-
86
Research Committee of the British Thoracic Society .
First randomized trial on treatments for pulmonary disease caused by M. avium-intracellulare, M. malmoense, and M. xenopi in HIV-negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Thorax.
2001;
56
167-172
-
87 Woods G L, Brown-Elliott B A, Desmond P E et al.. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard. NCLLS document M-24-A. Wayne, PA; National Committee for Clinical Laboratory Standards 2003
-
88
Wallace R J, Brown-Elliot B A, Ward S C et al..
Activities of linezolid against rapidly growing mycobacteria.
Antimicrob Agents Chemother.
2001;
45
764-767
-
89
Wallace R J, Brown-Elliott B A, Crist C J, Mann L, Wilson R W.
Comparison of the in vitro activity of the glycyicycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycicline against isolates of nontuberculous mycobacteria.
Antimicrob Agents Chemother.
2002;
46
3164-3167
-
90
Hadjiliadis D, Adlakha A, Prakash U B.
Rapidly growing mycobacterial lung infection in association with esophageal disorders.
Mayo Clin Proc.
1999;
74
744-745
-
91
Ebert D L, Oliver K N.
Nontuberculous mycobacteria in cystic fibrosis.
Infect Dis Clin North Am.
2002;
16
221-234
Leonid HeifetsM.D. Ph.D. Sc.D.
National Jewish Medical and Research Center
1400 Jackson St., Denver, CO 80206
Email: HeifetsL@njc.org
